Drug Profile
Fentanyl iontophoretic - ALZA Corporation
Alternative Names: E-TRANS fentanyl; Fentanyl HCI; Fentanyl iontophoretic transdermal system; Fentanyl transdermal - ALZA Corporation; IONSYS; SyB P 1501Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator ALZA Corporation
- Developer The Medicines Company
- Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Postoperative pain
Most Recent Events
- 06 Jan 2020 The Medicines Company has been acquired by Novartis
- 09 Feb 2018 SymBio Pharmaceuticals terminates a phase III trial for Postoperative pain due to the announcement for completion of the termination of development of SyB P-1501 in Japan (Transdermal) (NCT03005899)
- 09 Feb 2018 Discontinued - Phase-III for Postoperative pain in Japan (Transdermal)